Viewing data from:

CLORAZEPATE DIPOTASSIUM

ANDA

CLORAZEPATE DIPOTASSIUM | A071242 | USL PHARMA INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Clorazepate Dipotassium (2023)

Total Spending

$16.6M

Total Claims

143,857

Beneficiaries

26,466

Avg Cost/Unit

$1.86

Spending Trend

$23.3M(2019)→$21.9M(2020)→$19.8M(2021)→$18.8M(2022)→$16.6M(2023)

YoY Change:-0.8%

5yr CAGR:+1.9%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain4 active DMFs5 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

CAMBREX PROFARMACO MILANO SRLCLORAZEPATE DIPOTASSIUM

DMF 42401981

TARO PHARMACEUTICAL INDUSTRIES LTDCLORAZEPATE DIPOTASSIUM USP

DMF 141691999

HONOUR LAB LTDCLORAZEPATE DIPOTASSIUM

DMF 374752022

APITORIA PHARMA PRIVATE LTDCLORAZEPATE DIPOTASSIUM USP

DMF 413372025

SANOFI SAInactiveCLORAZEPATE DIPOTASSIUM

DMF 42571981

ABBVIE INCInactiveCLORAZEPATE DIPOTASSIUM (TRANXENE)

DMF 45351982

FABBRICA ITALIANA SINTETICI SPAInactiveCLORAZEPATE DIPOTASSIUM

DMF 59221985

WISCONSIN ANALYTICAL AND RESEARCH SERVICES LTDInactiveCLORAZEPATE

DMF 72621987

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveCLORAZEPATE DIPOTASSIUM USP

DMF 169802003

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 3.75MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Jun 23, 1987

No patent or exclusivity listings for this strength.